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Abbreviations 
Aβ: amyloid beta peptide; AD: Alzheimer’s disease; ALS: amyotrophic lateral sclerosis; 
APP: Amyloid precursor protein; CNS: central nervous system; EAAT: excitatory amino acid 
transporter; GFAP: glial fibrillary acidic protein; GABA: γ-aminobutyric acid; GAT: γ-
aminobutyric acid transporter; GLUT: glucose transporter; GlyT: glycine transporter; 5-HT: 
5-hydroxytryptamine, serotonin; MCT: monocarboxylic acid transporters; NMDA: N-methyl-
D-aspartate; SERT: serotonin transporter; SGLT: sodium-glucose symporter; S100B: S100 
calcium-binding protein B. 
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Abstract 
Astrocytes play a fundamental role in maintaining the health and function of the central 
nervous system. Increasing evidence indicates that astrocytes undergo both cellular and 
molecular changes at an early stage in neurological diseases, including Alzheimer’s disease. 
These changes may reflect a change from a neuroprotective to a neurotoxic phenotype. 
Given the lack of current disease modifying therapies for Alzheimer’s disease, astrocytes 
have become an interesting and viable target for therapeutic intervention. The astrocyte 
transport system covers a diverse array of proteins involved in metabolic support, 
neurotransmission and synaptic architecture. Therefore, specific targeting of individual 
transporter families has the potential to suppress neurodegeneration, a characteristic 
hallmark of Alzheimer’s disease. A small number of the four hundred transporter 
superfamilies’ are expressed in astrocytes, with evidence highlighting a fraction of these are 
implicated in Alzheimer’s disease. Here we review the current evidence for six astrocytic 
transporter subfamilies involved in Alzheimer’s disease, as reported in both animal and 
human studies. This review confirms that astrocytes are indeed a viable target, highlights the 
complexities of studying astrocytes and provides future directives to exploit the potential of 
astrocytes in tackling Alzheimer’s disease. 
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Introduction  
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterised by 
deposition of amyloid plaques, neurofibrillary tangle formation, synaptic loss and neuronal 
cell death (1). Whilst understanding of AD pathology has been predominantly ‘neurocentric’, 
recent advances in techniques and experimental models provide some valuable insights into 
astrocytes in AD pathogenesis (2,3). Astrocytes are present in the nervous system in 
approximately equal numbers to neurons (4), and have intimate physical connections with 
synapses and blood vessels. An appreciation of the diverse range of roles they play has 
gathered pace in the last 20 years (5,6). Far from being passive bystanders as once thought, 
strong evidence highlights astrocytes as dynamic components of CNS physiology and 
pathophysiology. For example, through cellular connections with brain endothelial cells, 
astrocytes regulate neurovascular coupling which ensures activity-dependent metabolite 
supply to neurons, and as cellular partners of neurons at synapses, astrocytes regulate 
potassium ions, hydrogen ions and take up neurotransmitters to influence synaptic signalling 
and plasticity (7–9).  Alteration in astrocyte functions could contribute to AD processes; 
namely, synaptic loss, neurodegeneration, amyloid deposition and tangle formation. Indeed, 
it is found that regional specificity, initially considered to be a neuronal phenomenon, also 
applies to astrocytes(10,11).  
While there is no or little astrocyte loss, both human post-mortem and animal studies show 
there is a distinct change in astrocyte morphology and physiology associated with pathology 
(12–14). Research to date indicates that the number of astrocytes remains consistent in 
post-mortem brains as well as in animal models of AD (overexpression of Aβ) as determined 
by immunostaining with available astrocytic markers (GFAP, S100B and glutamine 
synthetase) (15–17). This change in phenotype is most often reported as an increase in 
astrocyte reactivity, as visualised by increased protein levels of the intermediate filament, 
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glial fibrillary acid protein (GFAP). Increases in GFAP coincide with astrocyte hypertrophy 
and changes in morphology (18). While the number of reactive astrocytes correlates well 
with disease state in animal models (18,19), it is important to note that human studies have 
revealed increased astrocyte reactivity is not only associated with disease, but also reflects 
ageing (12). In several transgenic mouse models of AD; astrocyte reactivity occurs before 
detectable amyloid plaque deposition (20,21) and therefore may be regarded an early 
marker of pathology (Figure 1). Currently there is debate on whether reactive astrocytes 
contribute to neurodegeneration, or are indeed neuroprotective (22). Although it is usually 
GFAP which is measured, astrocyte reactivity is associated with a wealth of molecular 
changes which are incompletely characterised (18), and characterisation of these molecular 
changes can provide insight into disease process and potential therapeutic targets. 
Astrocyte functional capacity is a consequence of a complex transcriptome (23,24), and 
astrocytes express numerous receptors, transporters and signalling molecules which allow 
them to regulate CNS homeostasis, provide neuroprotection, and contribute to 
neurodegeneration.  Amongst the proteins pivotal in the maintenance of cellular and system 
homeostasis are transporter proteins, with over four hundred superfamilies’ (25). Astrocytes 
express a variety of transporters, with subfamilies and splice variants adding to their diversity 
(26–28). With a lack of AD-modifying treatments and an urgent need for new molecular 
targets to enter the discovery pipeline, astrocytic transporters provide an avenue for further 
research and development. Here we review evidence for the modulation of astrocyte 
transporters in AD and the implications for future treatment opportunities. Transporters 
include a diverse group of protein families with numerous members and a suitably diverse 
nomenclature. The rich diversity is evident in the topology of the transporters, with highly 
variable regions connecting transmembrane domains (Figure 2). For the purposes of this 
review, we have used the IUPHAR transporter nomenclature (29). A survey of the literature1 
                                               
1
 The authors restricted their search to PubMed using search terms: ‘astrocyte and Alzheimer’s 
disease’, ‘astrocyte transporters and Alzheimer’s disease’. Phrases combining Alzheimer’s disease 
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revealed several families that have been implicated in AD pathology (Table 1) and some of 
the major families are discussed below. 
1. SLC1 Amino acid transporters  
The SLC1 amino acid transporter family comprises five high affinity glutamate (SLC1A1-3 
and 6-7) and two neutral amino acid transporters (SLC1A4,5) with regional and cell type 
specific expression throughout the CNS (30). Glutamate transporters are predicted to 
contain eight transmembrane domains with two membrane re-entrant loops, and exist as 
homotrimers (see Figure 2A; 31). 
The glutamate transporters regulate glutamate homeostasis at both synaptic and 
extrasynaptic sites through active uptake of glutamate. Cellular uptake of glutamate is 
coupled with three Na+ and one H+ and counter transports one K+ (32). This process is 
secondary-active transport, as glutamate uptake does not directly involve ATP catabolism 
but is instead dependent on ionic gradients generated by ATP-dependent pumps, in 
particular Na+/K+ ATPase (see section 5). It is well established that an important  function of 
these transporters is to prevent glutamate-induced excitotoxicity at the synapse (Figure 3), 
believed to be causative in neurodegeneration (33). Given this pivotal role, these proteins 
have been the focus of numerous studies of neurodegeneration (e.g. 32–34) and there is a 
wealth of data available with respect to their modulation in AD pathology. 
EAAT2 (SLC1A2; rat GLT-1) is a transmembrane protein predominantly expressed in 
astrocytes and responsible for approximately 95% of all L-glutamate uptake in the CNS 
(30,37,38). Along with the uptake of glutamate from the synaptic cleft, EAAT2 is an important 
component of the glutamate:glutamine cycle (39,40) involved in the detoxification of 
glutamatergic signalling. EAAT1 (SLC1A3; rat GLAST) is also expressed at the membrane 
of astrocytes and mediates around 5% of the total glutamate transport in the adult CNS (41). 
                                                                                                                                                  
and individual transporters, for example, ‘EAAT2 and Alzheimer’s disease’ were also included in the 
search.  
7 
 
In relation to AD, these astrocytic transporters are most important given their contribution to 
total glutamate uptake and their predominant expression in brain regions susceptible to AD 
pathology (42). Arguably the most important of these transporters is EAAT2; indeed, the 
small contribution of EAAT1 to total glutamate uptake has left its role in neurodegenerative 
diseases, particularly AD, largely unknown. 
Mouse models have been a rich source of information with regards AD pathology, but 
provide conflicting data regarding the role and regulation of glutamate transporters. In terms 
of mouse AD models (which overexpress Aβ but do not recapitulate all the pathological 
features in human AD), there is a mixed picture of glutamate transporter alterations. The 
human amyloid precursor protein (APP; hAPP695 (V642I)/APP/Ld) model (43) showed no 
significant changes in EAAT2 or EAAT3 mRNA levels between genotypes; however 
transgenic animals displayed reduced Bmax and KD for [
3H] D-aspartate uptake along with 
significantly decreased EAAT2 and EAAT1 protein levels as analysed by 
immunohistochemistry (44). In the APP/PS1 model (45), both EAAT2 and synaptophysin 
protein levels do not change over the lifetime of these mice. To further understand a role for 
EAAT2 in regulating the progression of AD pathology, APP/PS1 mice heterozygous for 
EAAT2 (EAAT2het/APP/PS1) were generated. While long term deficits (9 months) in 
cognition and Aβ load where comparable to wild type mice, there was evidence of early 
deficits in memory tasks and Aβ load at 6 months for the heterozygous mouse (46).  In 
another APP transgenic mouse (APP23 mice) EAAT1 and EAAT2 protein levels in both the 
cortex and hippocampus show an age dependent decrease which preceded amyloid plaque 
deposition and gliosis (47). These studies suggest that loss of the EAAT protein renders the 
brain more vulnerable to neurological insults, including Aβ production.   
The triple transgenic (3xTg-AD) mouse (48) shows no changes in cortical EAAT2 expression 
or distribution (49). This contrasts with the report by Zumkehr et al. (2015) which highlighted 
significant decreases in hippocampal EAAT2 protein and mRNA in a disease dependent 
manner (50). The contrast in observations may highlight regional deficits in EAAT2 (cortical 
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vs hippocampal) or approaches to qualitative analysis. From a therapeutic stand point, 
increasing levels of EAAT2 through chronic administration of ceftriaxone restored cognitive 
deficits without impact on the amyloid load (50).  
Given that AD is a human disease, human tissue remains the most insightful as to 
monitoring pathological changes. The findings from mouse models are in contrast to human 
data (see below) and highlights the complexity of sporadic human AD and also questions the 
relevance of mouse models of AD (51). Radiolabelling and immunohistochemical techniques 
provided initial insight into changes in EAAT protein levels and activity in post-mortem 
human tissue. An early study looked at EAAT2 substrate uptake and reported an AD-related 
decrease of around 30% in aspartate uptake (52). This study highlighted that a functional 
deficit in EAAT2 may underlie synaptotoxic elements of AD pathology. Subsequent studies 
have looked at biochemical changes in EAAT2 and reported a decrease in EAAT2 protein 
levels within AD brains (12,53–56). Studies have suggested a link between EAAT2 reduction 
and APP processing (56), Braak stage progression in AD (12), amyloid plaque deposition 
(55)  and  cognitive impairment (57). However there are conflicting reports as to changes in 
EAAT2 mRNA levels observed in AD brains; studies have highlighted no change (56) or a 
decrease (54,55) in EAAT2 mRNA in AD tissue compared to controls. Therefore, evidence 
exists for both pre and post transcriptional regulation of EAAT with reference to AD 
pathogenesis. While the above studies point to a reduction in EAAT2 in human AD, this is 
contested in other studies (58). As technology advances and the ability to monitor EAAT 
function through positron emission tomography becomes available (59), the regulation of 
EAAT2 in AD may become clearer.  
The development of sophisticated gene profiling techniques (Gene Chip arrays, RNA 
sequencing) has allowed large-scale quantitative gene analysis of AD human tissue and age 
matched controls. These techniques have revealed decreased EAAT2 mRNA levels in 
hippocampal tissue taken from stage III-VI patients. Furthermore, the same study highlighted 
a localisation that correlated with neurofibrillary tangles and Aβ positive plaques (55). The 
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idea that changes in EAAT2 expression reflect disease progression is further supported by 
work using human hippocampal membrane preparations, detailing that the progression from 
mild cognitive impairment (MCI) to AD involves significant decreases in EAAT2 protein levels 
(60). Analysis of prefrontal cortex samples from Harvard Brain Tissue Resource Centre 
showed that AD tissues show greatly reduced protein and mRNA expression of EAAT2 (54). 
Fewer reports have looked at EAAT1 expression in human AD post-mortem tissue and 
present contrasting findings. Protein and mRNA levels of EAAT1 in the frontal cortex are 
reportedly unchanged between AD groups and control (56). EAAT1 mRNA and protein has 
been shown to be reduced in prefrontal cortex from AD samples (54). Hippocampal regions 
also show pronounced loss of EAAT1 mRNA, particularly in later stage AD (55). Likewise, 
gene chip arrays and RT-PCR showed EAAT1 to be significantly reduced in the 
hippocampus and middle frontal gyrus (12% and 18% respectively) of AD brains. 
Interestingly,  EAAT1, normally expressed exclusively in astrocytes, has been shown to co-
localize with tau in cortical pyramidal neurons of AD human tissues, suggesting an intriguing 
potential link between aberrant EAAT1 expression and AD pathology (61). 
Relevance to Alzheimer’s disease 
Glutamate is the major excitatory neurotransmitter in the central nervous system, and 
glutamatergic neurons are located in areas that are targeted by the AD pathological cascade 
(62,63). Disruption in glutamatergic signalling has been reported in both animal models of 
AD and people with dementia (62,64). Indeed a breakdown in glutamate homeostasis forms 
the basis of the ‘glutamatergic’ hypothesis in AD (65–67). It is also noteworthy that current 
symptomatic relief for AD is provided by memantine, a metabotropic glutamate receptor 
antagonist. Therefore the astrocyte-specific EAATs offer an intriguing therapeutic target (68–
70) for manipulating excessive glutamate levels as described in AD.  
Preclinical animal studies had highlighted the potential of the β-lactam antibiotic, ceftriaxone, 
to increase glutamate transport (71–74). However, this was not shown further in clinical trials 
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investigating the efficacy of ceftriaxone for the neurodegenerative condition amyotrophic 
lateral sclerosis (ALS) (75). This has stimulated researchers to adopt new approaches in 
order to develop compounds that can activate EAAT protein expression at a translational 
level (76). High throughput screening has revealed a number of compounds that act as 
EAAT2 activators in expression systems (71,76,77), thus acting to maintain extracellular 
glutamate concentration at physiological levels (in the low micromolar range). Most recently, 
a small molecule activator has been developed and characterised in animal models of 
neurodegeneration (78,79). In an ALS rodent model, the novel EAAT2 activator delayed 
motor function deficits and prolonged lifespan (78). How this will translate to treating humans 
remains to be seen, but any impact on disease onset would offer real hope to those at risk of 
developing AD or those in the early stages of the disease. Providing neuroprotection through 
modulation of EAAT function is therefore possible in animal models of disease; however the 
challenge will be translating these findings into a clinical application (80). Therefore, it 
remains to be seen which methods to target astrocytic glutamate transport will provide a safe 
and long term therapeutic benefit to all AD patients.  
2. SLC2A Glucose Transporters 
There are three families of glucose transporter proteins in mammals, each with multiple 
isoforms. These are the facilitative hexose transporters (GLUTs) of the SLC2 family, the 
sodium-glucose symporters (SGLTs) of the SLC5 family and the more recently characterised 
glucose transporters of the SLC50 family (SWEETs). The SLC2 family members; GLUT1 
(SLC2A1), GLUT2 (SLC2A2), GLUT3 (SLC2A3), GLUT4 (SLC2A4), GLUT6 (SLC2A6), 
GLUT8 (SLC2A8), GLUT9 (SLC2A9), GLUT10 (SLC2A10), GLUT11 (SLC2A11) and 
GLUT12 (SLC2A12) have twelve transmembrane domains and transport glucose (see 
Figure 2B; 80). The SLC5 family mostly have fourteen transmembrane domains whose 
family members SGLT1 (SLC5A1), SGLT2 (SLC5A2), SGLT4 (SLC5A9), SGLT5 (SLC5A10) 
and SMIT1 (SLC5A3) mediate active transport of glucose against its concentration gradient 
(82). Currently SWEET1 (SLC50A1) is the only reported SLC50 family member to be 
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expressed in mammalian cells and is predicted to have seven transmembrane domains (83). 
Also relevant to the uptake of metabolic fuels for CNS metabolism are monocarboxylic acid 
transporters (MCTs) of the SLC16 family allowing facilitative transport of lactate and 
pyruvate, namely MCT1 (SLC16A1), MCT2 (SLC16A7), MCT3 (SCL16A8) and MCT4 
(SLC16A3) (84).  
The CNS, without its own significant fuel stores, is critically dependent on uptake of glucose 
from the bloodstream. The brain accounts for at least 20% of whole body glucose utilisation 
(85).  A summary of the cellular expression of the main glucose and MCTs in human and 
rodent CNS is provided by Nijland et al. (2014). The glucose transporter GLUT1 (SLC2A1) 
accounts for the majority of glucose entry into CNS tissue through brain vascular endothelial 
cells, although there is evidence that SGLTs can also contribute to this process (87). The 
main astrocytic glucose transporter is GLUT1, while neurons, by contrast, express mainly 
GLUT3 which has a higher transport activity than GLUT1 (88). In addition, both astrocytes 
and neurons also express the insulin-regulated glucose transporter GLUT4 (88).  In relation 
to the MCTs, there is a cell specific pattern with astrocytes expressing MCT1 and MCT4 
(89,90), while neurons express MCT2 which displays a higher substrate affinity than MCT1 
(84). 
Neuronal function is absolutely dependent on supply of metabolic fuel, and to this end 
neuronal activation is efficiently coupled to energy utilisation and increased blood flow (85). 
Astrocytes represent an essential cellular link required for this neurovascular coupling and 
are therefore considered vital for the effective supply of blood and oxygen to meet the 
metabolic needs of neurons. Following glucose uptake, astrocytes can synthesise and store 
glycogen (91). Breakdown of glycogen in astrocytes is not able to protect the CNS from 
hypoxia, but can provide short term support to neurons when blood glucose availability does 
not meet demand (91). There are several models and some controversy about the metabolic 
substrate supplied by astrocytes. Magistretti and colleagues have proposed the glucose-
lactate shuttle, whereby glucose taken up by astrocytes via GLUT1 is metabolised to lactate 
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by glycolysis. Lactate then exits astrocytes via MCT1 and MCT4 and is taken up by neurons 
through MCT2, where it can be oxidised in the TCA pathway (Figure 3; 92,93). Other 
investigators suggest that glucose which is transported into the CNS through capillary 
endothelial cells avoids astrocytes entirely, and is in fact taken up directly into neurons via 
GLUT3 (94).  Other models show glucose uptake via astrocytes at the capillary surface and 
released directly at synapses to be taken up by neurons (95).  
While debate surrounds astrocytic metabolic supply and demand, it is clear that brain 
glucose metabolism is decreased in preclinical patients (96), animal models of dementia (97)  
and people with a diagnosis of AD (98). The molecular mechanisms behind this are poorly 
understood, although human AD studies highlight that astrocyte/endothelial GLUT1 (as well 
as neuronal GLUT3) levels are reduced in post-mortem AD brains (99,100). Loss of 
astrocyte glucose transporters (GLUT1) is also found in the arcAβ (expressing both the 
Swedish and Arctic APP mutations) transgenic animal model, with no detectable changes in 
neuronal glucose transporters (97).  
Relevance to Alzheimer’s disease 
Perturbed glucose metabolism is a contributing factor to the pathogenesis of AD 
(97,101,102). This disruption is reported to be one of the earliest features of AD, in that a 
reduction in brain glucose metabolism can be detected (103) and is used as a diagnostic tool 
(104). However a much more dynamic picture of glucose metabolism is emerging (105,106), 
with reference to timeline and impact of ageing.  
Recent work suggests that contribution of astrocytic glucose transporters is less significant 
than the importance of the vascular endothelial transporters (107). Further work also 
suggests that glial glucose transporters might not provide an appropriate target for 
preventing AD: as in drosophila AD models overexpression of GLUT1 in glia had no effect 
against Aβ induced neurotoxicity (108). However, this lack of effect could have been due to 
the genetic approaches used in this specific study and provides a cautionary tale in terms of 
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interpreting genetic studies. In contrast, studies have highlighted a role for GLUT1 in 
memory formation and that GLUT1 induction is not mirrored by the neuronal GLUT3 protein 
(109). This indicates a level of selectivity for the astrocytic GLUT1 protein which seems to be 
task dependent. This remains to be therapeutically exploited. Therapeutic interventions 
seeking to enhance astrocytic lactate transport may provide a more fruitful endeavour. MCT1 
knockout mice show deficits in long term memory (109) and there is clear evidence that 
MCT1 and MCT4 are critical for memory formation in the hippocampus (110). The cancer 
field has developed some non-specific MCT inhibitors (111) which are currently in clinical 
trials (AZD3965; http://www.clinicaltrials.gov/show/NCT01791595). There remains the 
potential for these inhibitors developed further in a neuroscience context. 
Metformin, the antidiabetic drug, has received a lot of attention with regards to its potential 
act as a novel therapeutic strategy in managing AD (112–114). This links into the emerging 
hypothesis that AD should be classed as a third type of diabetes (115,116). However, 
reports are conflicting as to its effectiveness as a therapeutic intervention and the risk of 
developing AD (117,118). This may underlie the fact that the extent of metformin’s molecular 
pharmacology is still under investigation (31,119,120). In relation to transporter activity, 
reports have highlighted that GLUT4 translocation could potentially underlie its regulation of 
glucose metabolism (121). Modulation of the GLUT4 transporter to elevate glucose levels to 
maintain physiological levels may provide a potential route for pharmacological intervention. 
However, given the dynamic regulation of this transporter via endogenous means (e.g. 
increasing energy demands; see (122)) using intrinsic mechanisms rather than exogenous 
applications may prove to be a better therapeutic strategy to target GLUT4 in the fight 
against AD (123). Longer term studies are needed to reveal the role of metformin 
administration in human subjects and the elevated risk, if any, of developing AD. Here there 
is a particular interest in the APOE-ε4 genotype given its known associated risk with AD 
(124).   
14 
 
Astrocytes have a greater glycolytic capacity than their neuronal counterparts (125,126); 
indeed, this may contribute to the resilience against Aβ accumulation in contrast to the 
catastrophic neuronal loss (127). It is interesting that most transgenic rodent models fail to 
reproduce neuronal loss on the same scale as the human disease. This may indicate a 
species-specific expression of key metabolic enzymes, such as PDK1. This could lead to 
drug discovery programmes targeting these enzymes. However, this may be a short term 
protective mechanism prior to symptom onset. The long-term potential of aerobic glycolysis 
to match the continual decline in glucose availability remains to be determined, however 
transporter activity can feed into this enhancement of astrocytic metabolism. For example, 
BDNF, which has received a lot of interest as an Alzheimer’s therapeutic target (128), has 
been shown to modulate the expression levels of GLUT3 with astrocyte transporter levels 
not determined (129). Furthermore, lactate can stimulate BDNF production in both human 
astrocytes and SHSY5Y cells in a time-dependent manner (130). Such studies highlight the 
importance of a therapeutic timeline in which to stimulate astrocytes to respond to the 
growing deficits in neuronal energy supply. 
There are some indirect interventions which may lead to improved glucose metabolism in 
AD. For example, a recent study has reported the use of a cannabinoid receptor type 2 
agonist to enhance CNS glucose uptake (131). Interventions targeting β-adrenoceptors, 
which induce glucose uptake and storage and breakdown of glycogen in astrocytes, also 
have promise to improve the supply of glucose and lactate to neurons and modify disease 
progression (132,133). 
Multiple mechanisms, some restricted to astrocytes, can therefore influence brain 
metabolism. The challenge is to generate specific compounds that target these proteins; 
which may be through direct interaction with the astrocyte transporters or indirectly through 
modulation of cellular processes that impact of energy metabolism. What is clear is that 
astrocytes are key to the regulation of brain glucose metabolism and should be considered 
as part of a solution in redressing the energy deficit in neurodegeneration. 
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3. SLC6 Neurotransmitter Transporters 
The neurotransmitter family (SL6) incorporates GABA, glycine, monoamine and neutral 
amino acid transporters. Neurotransmitter transport is Na+ and Cl- dependent, with the 
stoichiometry of ionic coupling being subfamily specific (134). The predicted topology of 
twelve transmembrane domains (see Figure 2B; 108) has been confirmed from crystal 
structure studies using a prokaryote homologue, the leucine transporter (LeuT; (136)). These 
transporters are expressed throughout the CNS and are critical in maintaining physiological 
levels of neurotransmitters making them an interesting target for therapeutic intervention. 
GABA and glycine are vital inhibitory neurotransmitters influencing information processing, 
network synchrony and neuronal plasticity. An imbalance in excitatory and inhibitory 
neuronal activity has been implicated in AD, with a focus on modulating excitation to reduce 
neurodegeneration associated with excess excitatory tone  (33). The ability of astrocytic 
GABA and glycine transporters to suppress excitation has previously been demonstrated 
(137,138). To date there has been limited research into these transporters and their 
involvement in AD.  
Astrocytes show a predominant expression of the GAT3 (SLC6A11) protein, with GAT2 
(SLC6A13) and BGT-1 (SLC6A12) also expressed but not exclusively in astrocytes (139). 
Disruption of GABAergic systems has been implicated in the pathogenesis of AD (140). Loss 
of GABAergic terminals has been reported in human AD brain (141), network imbalance in 
the hAPPJ20 transgenic model of AD has been linked to reduced GABAergic activity (142) 
and transplantation of GABAergic interneurons restores AD related cognitive decline in mice 
(143).  The strongest evidence for a role of astrocytes has come from research by Wu et al., 
(2014), looking at both transgenic models of disease and human tissue. Using the 5xFAD 
model of disease (144) they reported both neuronal and astrocytic GABA modulation, high 
GABA content in astrocytes and upregulation of the α5 subunit of the GABAA receptor. 
Astrocyte enriched GAT3/4 (SLC6A11; human GAT3/mouse GAT4) was implicated in 
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releasing excess GABA leading to elevated tonic inhibition of signalling in the dentate gyrus 
(Figure 3). GABA transporters can operate in either direction, either taking up or releasing 
GABA, in both physiological and pathological conditions (145).  
Wu et al., (2014) highlighted that modulation of GAT3/4 could be a novel AD therapy, 
although current pharmacological tools would need to be developed for this purpose. 
Furthermore, they suggest that increased astrocytic GABA content may provide a biomarker 
for AD; increases in GABA occurred in line with development of Aβ deposition. Highlighting 
the need to replicate AD animal model studies in humans, Wu et al., (2014) also observed 
increased GABA content in human AD samples, giving further weight to the role of astrocytic 
GABA in AD. There are interesting links to the loss of GABAergic signalling with ageing and 
APoE4 expression (143,146), two known risk factors for AD. Whether this is an astrocyte-
dependent process merits further investigation. It remains to be determined if GABAergic 
dysfunction is found in all forms of AD, which will impact on the drug development targeting 
the astrocytic GABA transporters.  
In comparison, glycine transport has so far received little attention in the field of AD. 
Astrocytes express the GlyT-1 (SLC6A9) transporter; although expression is not restricted to 
astrocytes. Furthermore there is conflicting evidence as regards the expression of GlyT-2 
(SLC6A5) with early studies suggesting a neuronal specific isoform and later studies 
proposing a neuronal and astrocyte localisation (28,137,147); differences in cellular 
preparations may underlie these discrepancies. Importantly glycine is a co-agonist of the 
NMDA receptor which has been linked to AD pathology (148). A study by Timmer et al., 
(2014) indicated a decrease in the levels of glycine in an animal model of AD which they 
proposed may influence the glutamatergic system via NMDA receptors (149). Therefore, 
mechanisms to increase synaptic glycine levels could be exploited to restore NMDA 
signalling which is lost in AD. To this end, a GlyT-1 inhibitor (ASP2535) improved cognition 
in the scopolamine-induced model of AD, signalling the potential for targeting glycine 
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transport (150). However, the failure of this model to replicate the progressive nature of the 
AD limits our interpretation (151). 
The serotonin transporter (SERT, SLC6A4), which facilitates transport of 5-
hydroxytryptamine (5-HT, serotonin), has largely been perceived as neuronal specific (152). 
However studies have shown the expression of functional SERT in astrocytes (27,153,154). 
These studies have been carried out in a range of in vitro preparations, so the significance of 
SERT astrocytic expression in vivo remains unresolved. Increasing evidence highlights a 
role for 5-HT in AD pathogenesis; human studies indicate a loss of 5-HT (155) and changes 
in 5-HT receptor levels (5-HT1A, 5-HT2A, 5-HT4 and 5-HT6) in AD brains (156–160).  A 
number of 5-HT6 antagonists are currently in clinical trials as so-called cognitive enhancers 
(161,162). Their ability to improve cognition is linked to modulation of the cholinergic and 
glutamatergic signalling rather than alterations in 5-HT levels (163,164). Furthermore there is 
recent evidence that may suggest a role for SERT in AD pathology (165,166). Human data 
presents an interesting debate surrounding polymorphisms within the SLC6A4 gene, with 
studies reporting an association with the etiopathogenesis of AD (167–169) and others the 
contrary (170–172).  
Relevance to Alzheimer’s disease 
Disrupted neurotransmitter signalling has long been associated with AD pathology (65,173). 
While much of the research focuses on the cholinergic and glutamatergic pathways, recently 
scientists have proposed changes in a host of other neurotransmitters (174,175).  
Based on preclinical work, AD therapy would look to inhibit astrocytic GATs which would 
reduce tonic GABAergic inhibition and improve cognition. To date, GAT1 inhibitors have 
been developed for the treatment of epilepsy (e.g. tiagabine; (176)). In addition, a GAT2 
inhibitor, EF1502, has been used in preclinical studies and showed additional anticonvulsant 
effects when administered with tiagabine (177,178). While we await clinical development of 
astrocyte specific GATs inhibitors, examining astrocyte GABAergic transport may provide 
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both insight into potential biomarker validation (astrocyte GABA content) and the efficacy of 
targeting astrocytic GABA transporters in combatting AD pathology. 
While the contribution of astrocyte-mediated uptake of serotonin is not completely 
established, it is possible that they are targets for AD therapeutics. Given that both 
antagonists and agonists of 5-HT6 receptors are reported to improve cognition, it is unclear if 
activation or inhibition of astrocytic SERT activity would benefit AD patients. To this end, the 
ability to pharmacologically target astrocyte rather than  neuronal  SERT will be a challenge, 
based on previous reports (179). Overall, modulation of 5-HT transport has the potential to 
modulate non-cognitive deficits in AD, such as depression; however, the use of selective 5-
HT reuptake inhibitors in AD shows limited efficacy (180). Where alterations in 5-HT 
transport may provide benefits in frontotemporal dementia, where the serotoninergic system 
is disrupted, although studies to date have showed that effects are limited to the non-
cognitive domains (181). 
Increasing NMDA mediated synaptic transmission via GlyT1 modulation may only serve to 
modulate disease progression at certain points in the pathogenesis of AD (i.e. prior to 
excitotoxic events; Figure 3). While this would not prevent the disease from developing, it 
may provide a disease-modifying treatment which would be a significant advance on the 
current symptomatic treatments available. However, it would not provide a long-term 
strategy to manage the disease as it progresses. This may highlight the need for a 
progressive strategy to tackle AD and finding the therapeutic window for different 
neurotransmitter targeted treatments and how to exploit them will be key to developing future 
therapeutic strategies. 
4. SLC3/SLC7 Heteromeric Amino Acid Transporters 
The cystine/Glu antiporter system xc– consists of two membrane spanning proteins: the light 
chain, XCT (SLC7A11) with twelve or fourteen transmembrane spanning domains that 
associates with the heavy chain protein 4F2hc (SLC3A2), also known as FRP (fusion 
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regulatory protein) and CD98hc. 4F2hc has a single transmembrane domain (see Figure 2C; 
152). Together these proteins mediate the heteroexchange of cystine and glutamate with a 
stoichiometry of cystine:glutamate of 1:1 at the plasma membrane. The complex can operate 
in either direction, but is generally considered to import cystine and export glutamate from 
the cell (183,184).  
In the CNS, system xc- is predominantly expressed on glial cells, particularly astrocytes 
(185). Astrocytes are rich in glutathione compared to neurons, and release glutathione which 
can then be taken up by neurons (186).  This mechanism is considered to be one of the 
most important ways that astrocytes confer neuroprotective effects, through reducing 
neuronal susceptibility to oxidative stress, and it is system xc- which controls glutathione 
levels: imported cystine is reduced intracellularly to cysteine, which is used in the synthesis 
of glutathione (GSH) (187). System xc- also mediates glutamate release from astrocytes 
(Figure 3). The non-vesicular (calcium-independent) glutamate release from astrocytes via 
system xc- is sufficient to activate neuronal glutamate receptors in the CNS and therefore 
system xc- directly contributes to neuronal excitability and synaptic plasticity (184,188,189).  
Relevance to Alzheimer’s disease 
In relation to system xc- as a therapeutic target, most published work to date has focused on 
developing methods to inhibit system xc- as it has been identified as a key system in several 
cancers. For AD, upregulation of system xc- activity should be disease-modifying by 
increasing glutathione; however, conversely, increased system xc- activity may contribute to 
increased extracellular glutamate levels, potentially leading to excitotoxic neuronal death 
(see Section 1). To date, however, there are no studies characterising changes in CT, 4F2hc 
levels or xc- activity in AD or animal models of AD disease. Nonetheless, neuroprotective 
properties of ceftriaxone in an animal model of motor neuron disease have been attributed to 
its ability to induce XCT (190) but, paradoxically, deletion of XCT reduces symptoms in a 
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transgenic mouse model of motor neuron disease (191). Therefore, it remains to be 
demonstrated if system xc- is a worthwhile target in the search for novel AD therapeutics.   
5. Na+.K+-ATPases 
The ubiquitous plasma membrane protein sodium-potassium ATPase (Na+.K+-ATPase), 
commonly known as the Na+ pump is classified as an enzyme (EC 3.6.3.9).  Na+.K+-ATPase 
is a primary active transporter transporting Na+ out of cells and K+ into cells against their 
concentration gradients with a stoichiometry of three Na+ exported for two K+ imported. 
Na+.K+-ATPase is a heterodimer of α and β subunits. α subunits have ten transmembrane 
domains (see Figure 2D) and possess all the essential domains for ATP hydrolysis and ion 
transport with four family members identified in man: α1 (ATPA1), α2 (ATPA2), α3 (ATPA3), 
α4 (ATPA4). Beta subunits are glycoproteins with a single transmembrane domain, of which 
there are four family members in man: β1 (ATPB1), β2 (ATPB2), β3 (ATPB3), β4 (ATPB4) 
(192). There are also γ-subunits of the FXYD protein family which alter Na+.K+-ATPase 
activity through modulating affinity for Na+ and K+(193).  
Most focus on the Na+ pump in the nervous system has been on its role in maintaining Na+ 
and K+ gradients in neurons, with estimates that 60-70% of energy utilisation in the CNS is 
thought to provide ATP to power Na+.K+-ATPase. While neurons express the α3 isoform, 
astrocytes predominantly express the α2 and α1 isoforms together with β2 (194–196). The 
α2 isoform has a higher Kd than the α1 isoform, suggesting that it is most important in 
astrocytes at times of high Na+ load, for example following neuronal activity (Figure 3). In 
those circumstances, there is a need for astrocytes to take up large quantities of glutamate 
via EAATs (see section 1) with a concomitant uptake of Na+. Supporting a close association 
between EAAT and Na+.K+-ATPase function, there is a physical interaction between the 
Na+.K+-ATPase α2 subunit and the major astrocyte SLC1A/EAATs: GLT-1 and GLAST (197) 
and stimulation of glutamate uptake results in an up-regulation of Na+.K+-ATPase activity 
(198). Disruption of astrocyte Na+.K+-ATPase activity, as found in human ATP1A2 gene 
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mutations, leads to both epileptic seizures and familial hemiplegic migraine: these two 
examples of neuronal hyperexcitability syndromes are likely a consequence of reduced 
ability of astrocytes to take up K+ (199).  Further supporting a role of astrocyte Na+.K+-
ATPase in supporting neuronal function, heterozygous mice with reduced Na+.K+-ATPase 
α2 subunit (astrocytes) or α3 subunit (neurons) display impaired spatial learning (200). In 
addition, protein levels of the α2 subunit have been shown to increase following inhibitory 
avoidance learning (109). 
In post-mortem AD brain tissue, there is a marked decrease in Na+.K+-ATPase α subunits as 
determined by binding of the Na+.K+-ATPase inhibitor, ouabain (201).  Ouabain is a pan 
Na+.K+-ATPase inhibitor displaying differing affinities for the three alpha isoforms and 
therefore does not discriminate between neuronal and glial α isoforms (202). Other studies 
have shown decreased Na+.K+-ATPase activity and α subunits with a concomitant decrease 
in α3 mRNA, but an increase in α1 mRNA, attributed to up-regulation of α1 mRNA rather 
than mRNA degradation in reactive astrocytes (203,204). Likewise, α3 subunit protein levels 
and Na+.K+-ATPase activity are reduced in a double transgenic (APP and PS-1) mouse 
model of AD (205). With reference to the glial isoforms, exogenous application of Aβ25-35 
resulted in a decrease in α1 subunit protein levels (206). Most recently, the α3 neuronal 
specific Na+.K+-ATPase isoform is a target for Aβ assemblies, presenting a potential novel 
therapeutic strategy (207).  
Relevance to Alzheimer’s disease  
Whether corresponding therapeutic opportunities exist to stimulate astrocyte Na+.K+-ATPase 
and confer neuroprotection is an open question. Alterations in Na+ and K+ concentrations 
have been reported in AD tissue (208), with some reports highlighting a two-fold increase in 
intracellular Na+ and a 15% increase in intracellular K+ (206). These concomitant increases 
in intracellular levels of both Na+ and K+ highlights that while changes in Na+.K+-ATPase 
activity may occur, they cannot contribute solely to the global changes reported in AD. It is 
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clear, however, that individual elements of AD pathology including amyloid beta peptide and 
oxidative stress can modulate learning and memory through modulation of Na+.K+-ATPase 
activity (209–211). This has led to an increasing number of Na+.K+-ATPase modulators 
being proposed as AD therapeutics (211). Many of these are preclinical observations tested 
in expression systems that remain to be robustly tested, of note however is the observation 
that currently approved AD therapeutics rivastigmine and memantine have been reported to 
increase Na+.K+-ATPase activity (212,213). At a molecular level, phosphorylation of the 
neuronal isoform is dynamically regulated by PKC and calcineurin (214,215). It is likely that a 
similar phosphorylation switch occurs in astrocytes, however given differences in Ca2+ 
sensitivity between the isozymes (α1β1 shows insensitivity to Ca2+; (216,217)) Na+ may play 
a more prominent role here. This reinforces the suggestion that regulation of Na+ 
homeostasis is of greater importance than Ca2+ in astrocytes (218,219).  
6. ATP-binding cassette transporter family 
ATP binding cassette (ABC) transporters are membrane proteins which facilitate ATP 
dependent movement of a diverse array of substrates. Individual subunits are typically 
comprised of two six transmembrane-spanning domains with two nucleotide binding 
domains (see Figure 2E). This architecture permits two modes of transport; namely import 
and export. Five subfamilies (ABCA, ABCB, ABCC, ABCD and ABCG) allow for the transport 
of a diverse range of substrates, including many therapeutic drugs. Furthermore, various 
isoforms within the subfamilies enhance both the cellular and substrate specificity.  
ABCA transporters (ABCA1-13) have been shown to regulate lipid transport and gene 
expression data highlights that human astrocytes express ABCA1-3 at the mRNA level 
(220). There is however contrasting evidence at the protein level (221,222). More recently, 
reports have detected expression of ABCA5 in astrocytes although to a lesser extent than 
neuronal expression (223). This is of interest given the observation that the ABCA5 
transporter has been linked to APP processing in vitro. This modulation of APP processing 
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resulted in a reduction of the Aβ1-40 and Aβ1-42 variants (223). While the role of the astrocytic 
ABCA5 in Aβ generation remains to be determined, it is clear that transporter function can 
be regulated by key elements of AD pathology. Further evidence is needed as to the nature 
of the astrocyte ABCA transporters with reference to their expression, at both the mRNA and 
protein level and to their functional activity. For example, ABCA7 has been strongly 
implicated in APP processing, Aβ generation and the onset of dementia (224,225). However, 
the individual cellular role(s) of ABCA7 remains unresolved, and this is key given its 
widespread distribution (220,225). This shortfall in our understanding currently limits a critical 
appraisal of the role these astrocytic transporters may play in revealing a novel strategy to 
better manage AD pathology. 
P-glycoprotein 1 (PGP,MDR1, ABCB1) is highly expressed in the blood brain barrier, with 
protein detected in both the endothelial component and astrocytes (226). Therefore these 
transporters have a key role in the elimination of Aβ from the brain, which is believed to be 
dysfunctional in late onset AD (227). Interestingly, when overexpressed in cancer cells, P-
glycoprotein 1 confers multidrug resistance through its export of cytotoxic messengers (228). 
In vitro evidence suggests that Aβ can act as a substrate for the transporters, and blockade 
of P-glycoprotein transport elevates extracellular levels of Aβ in a time dependent manner 
(229,230). Animal models of AD (3xTg and Tg2576) have revealed a link between both P-
glycoprotein 1 expression and activity in relation to disease progression (231,232). This 
evidence suggests that accumulation of the toxic form of Aβ can lead to downregulation of 
the P-glycoprotein 1 transporter. This correlates with human studies that reported elevated 
levels of Aβ and decreases in P-glycoprotein 1 levels (233,234). The relative contributions to 
Aβ clearance from capillaries and astrocytes remains to be fully understood. 
Multidrug resistance proteins (Mrps1-9) are members of the ABCC subfamily of the ABC 
transporters. Mrps are export pumps that use ATP to facilitate the efflux of organic cations 
(235). Regarding astrocyte expression, Mrp1 protein has been reported in rodent and human 
astrocytes (226,236); Mrp2 at the mRNA and protein level is lacking in astrocytes (237); 
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Mrp3-5 have been reported at both the mRNA level and protein levels in various astrocyte 
preparations (237,238). Evidence in the literature supports a role of Mrp1 in AD; however, 
this is not conclusive. For example, oxidative modifications of Mrp1 have been shown in AD 
brain, with lipid peroxidation a contributing factor (239). It remains to be see if this is a 
consequence of the disease process or a contributing factor.  
Relevance to Alzheimer’s disease 
There is a wealth of evidence that links lipid metabolism and AD (240,241) and this 
highlights the potential to target ABCA transporters given their role in cholesterol metabolism 
(222). This is pertinent for AD, given the genetic links to APOE-ε4 which is predominantly 
synthesised within astrocytes (242). While activation of the ABCA transporters can be 
achieved via agonists of the retinoid X receptor system (e.g. bexarotene), numerous other 
cellular proteins are targeted by this system and therefore this limits the selectivity of 
agonists (243). This led to the discovery of an ABCA1 agonist that increased transporter 
activity, with a subsequent rise in cholesterol efflux (244). The use of a small molecule 
ABCA1 agonist (CS-6253) has produced some interesting results both in vitro and in vivo. In 
vivo studies highlight that injection of the CS-6253 peptide can restore cognitive deficits in 
APOE transgenic mice (245), and the peptide can modulate both central and peripheral lipid 
metabolism (246). This gives a clear indication that ABCA1 transporters can reverse 
cognitive decline, through modulation of ApoE4. While work remains to be done to look at 
the specific signalling cascades involved, the preliminary results are promising. It would be 
of interest to see whether the activation of astrocytic ABCA1 contributed to these effects. 
This could be achieved using astrocyte-directed genetic strategies to selectively knock out 
ABCA1 in astrocytes. 
Mrps alongside P-glycoprotein-1 are of interest from an AD perspective given their 
expression in the cellular constituents of the blood brain barrier (BBB; (247)). Thus, they may 
provide a route by which to enhance toxic Aβ clearance from the brain or indeed to facilitate 
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transfer of a therapeutic agent into the brain. Aβ clearance is a subject of growing interest, 
albeit secondary to Aβ formation (248,249). Enhancing transporter mediator clearance of Aβ 
with a view to redressing the Aβ balance in the brain would be a therapeutic strategy worth 
pursuing. In support of this in vivo evidence highlights the upregulation of the P-glycoprotein 
transporters via pharmacological activation of the nuclear receptor pregnane X receptor 
(232). The diverse range of substrates for these transporters should facilitate drug discovery 
programmes to generate preclinical compounds of interest to the AD research community. 
Conversely, this may prevent the development of selective tools and another approach may 
be needed. One such strategy could explore transporter protein modification to alter the 
kinetics of Aβ efflux via the P-glycoprotein transporter. This type of strategy will be aided by 
the use of positron emission tomography (PET) studies, which can reveal P-glycoprotein 
transport kinetics in vivo (250,251). 
 
Future perspectives 
Our knowledge of the roles astrocytes play in both physiology and pathology has increased 
greatly in the last decade and they are now seen as pivotal parts of the complex cellular 
network that maintain CNS function. As such, they are becoming of interest in 
neurodegenerative research (252). Neurological disorders such as AD are difficult to 
combat, although recent clinical trials with the anti-amyloid antibodies, Solanezumab (Eli 
Lilly) and Aducanamab (Biogen), may provide some hope (253,254). Given the lack of 
success for novel therapies targeting neuronal entities, it is perhaps surprising that to date 
few astrocyte targets have been identified. Advances in technology have increased our 
understanding of astrocytes and their interactions (255), which is still limited by poor 
astrocyte-specific markers which lack the robust nature of neuronal markers (5). The 
publication of the astrocytic transcriptome (24) revealed potential new cellular biomarkers 
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that provide tools for generating specific therapeutic approaches to target astrocytes for the 
purpose of reducing neurodegeneration in AD.  
One challenge that still remains is understanding the heterogeneity of the astrocyte 
population (256) and being able to replicate this in experimental models. This may in part be 
overcome by the development of induced pluripotent stem cell (iPSC) technology. Again 
here, neuronal research has led the way and there is now an extensive research literature 
using this technology to further our understanding of neuronal cell death in AD (257–260). 
The ability to develop patient-derived cell lines gives researchers the opportunity to study 
disease pathology directly. In recent years investigators have developed methods to derive 
and maintain astrocytes from patient iPSCs (261–263). The question as to whether these 
cells truly represent functioning astrocytes in aged human brains remains to be answered 
(264). However initial studies have provided interesting insights into neurodegenerative 
diseases. Studies in AD-derived astrocytes are undoubtedly underway and we await the 
findings with interest.  
Using these tools will unravel the complex role of astrocyte transporters at both a cellular 
and network level. The interplay between individual astrocyte transporters is evident (e.g. 
Na+.K+-ATPase and SLC1A2/SLC1A3) and dysregulation of one set of transporters will 
impact on the functionality of other associated transporters (Figure 3). The challenge will be 
to dissect the timeline of this dysregulation to pinpoint molecular targets and their role in AD 
pathology. Many astrocyte proteins are intimately involved in the pathology of a disease 
which leads to neuronal cell death. Understanding if this dysregulation in transporter function 
occurs pre-symptomatically, and the preliminary research indicates that this is the case, will 
be key to determining a therapeutic strategy. This has been helped by a growing awareness 
of astrocytes and their biology in the last decade. The purpose of this review was to highlight 
changes in select astrocytic transporter families and in doing so highlight a host of potential 
targets for AD. These targets can be classified accordingly to biological research themes 
which cover key areas not only for AD research but neuroscience research in general 
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(Figure 4). For these targets to become a realisation in terms of clinical products will require 
further research efforts in translatable neuroscience with direct clinical applications, allowing 
us to cross the ‘valley of death’ in drug discovery to provide much needed therapies for 
tackling AD.   
Encouragingly some drugs target some transporters highlighted in this review (e.g. EF1502; 
Section 3), but with a lack of selectivity for astrocytic isoforms it will hopefully be the next 
generation of compounds that target astrocyte specific transporters. Preclinical strategies 
here could use chemogenetic delivery systems as described for selective targeting of 
astrocyte adenosine receptors (265). This allows for the modulation of target activity through 
delivery of a synthetic ligand and has distinct advantages over the invasive optogenetic 
approaches (266). While this chemogenetic approach works well for G-protein coupled 
receptors (GPCRs), it is unclear if this approach could yield positive results for transporter 
proteins which are not exclusively coupled in a similar fashion. Research into tailor-made 
delivery systems is on-going and with pharmaceutic companies waking up to the idea of 
using the so called ‘support cells’ to provide patient benefit (e.g. Astrocyte Pharmaceuticals), 
it will hopefully not be long before astrocyte-targeting drugs are being considered as viable 
therapeutic strategies to combat complex neurological conditions, including AD. 
Figures/Table:  
Figure 1. A timeline of astrocyte involvement in AD pathology. A schematic 
representation of how astrocytes are believed to be involved in the pathogenesis of AD. (A) 
GFAP expression is routinely reported to increase in animal models of AD, with available 
human data indicating this may relate to physiological ageing other than AD specifically. 
However, the phenotypic change presented is consistent and highlights that this switch 
occurs before both amyloid deposition and neurodegeneration. This therefore highlights the 
importance of astrocytes in the early stages of disease and with it the potential to target 
them for patient benefit. (B) Schematic representation of the phenotypic changes reported in 
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astrocytes from models of AD. (Left) A cartoon of a pre-symptomatic astrocyte showing 
elaborated processes and regulated volume. (Right) A cartoon of an astrocyte from an AD 
brain. Astrocyte atrophy is noted in several animal models of AD and can be defined by a 
variety of parameters including surface area. 
 
Table 1. An overview of the astrocyte transporters with proposed relevance to AD 
pathology. A review of the literature revealed several astrocytic transporters that have been 
implicated in AD pathology. Here we present an overview of the main protagonists, their 
reported involvement and models used to present lines of evidence, as discussed in the text. 
Where multiple substrates exist the predominant one is mention here. (TgAD= transgenic 
animal model). *it is unclear as to the contribution of astrocyte SERT to brain physiology; 
therefore, these observations may reflect neuronal SERT. #it is unclear the role of astrocyte 
ABCA7, expression levels are observed within all cells of the brain with microglia showing 
higher levels in comparison to neurones and astrocytes. 
 
Figure 2. Topology of the astrocytic transporters. A schematic representation of the 
topology of astrocyte transporters. The transporters illustrated here highlight the diversity 
amongst the transporter families. (A) SLC1 transporter is shown regarding Section 1; (B) 
SLC2, 6 and 16 are used to illustrate Sections 2 and 3; (C) A SLC7/SLC3 heterodimeric 
complex is shown to illustrate Section 4; (D) EC 3.6.3.9 is shown to highlight the interplay 
between α, β and γ subunits to make a functional transporter. This is highlighted in Section 
5; (E) MDR1 is shown as an illustration of the ATP-binding cassette transporter family. This 
family is discussed in Section 6. 
 
Figure 3. Astrocyte transporters coupled to AD signalling cascades. 1) EAAT2 
transports glutamate from the synapse into the cytosol using ionic currents generated from 
primary active transporters which breakdown ATP. Therapeutically increasing the activity of 
this transporter may reduce glutamate-induced excitotoxicity evident in Alzheimer’s disease 
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(AD). 2) Increasing GLUT1 levels or transporter activity could increase astrocyte glycolysis, 
improving the supply of lactate to neurons. Lactate can be taken up by neurons through 
MCT1 transporters. 3) GAT3 inhibition could limit GABA release from reactive astrocytes, 
preventing long term deficits in neuronal activity. Targeting reactive astrocytes this way could 
increase neuronal activity in AD. GlyT-1 transporter inhibition may potentiate NMDA 
signalling by increasing the bioavailability of glycine at the synapse. Glycine is a co-agonist 
of the NMDA receptor and could act to modulate glutamatergic neurotransmission. 4) 
Glutathione (GSH) is the predominant antioxidant in astrocytes and is depleted in AD brains. 
Increasing cystine transport, via modulation of System xc-, could boost GSH antioxidant 
capacity. 5) Targeting Na+/K+ ATPase could have mixed effects. Inhibition could decrease 
sodium efflux from astrocytes but dampen neuronal activity. Conversely, activation would 
stimulate neuronal activity through increasing synaptic Na+ concentration but delay 
repolarisation via increased K+ influx. Furthermore, due to the interaction between Na+/K+ 
ATPase and EAAT2, targeting this pump may impact glutamate uptake dynamics (numbers 
refer to the relevant sections within the text). 
 
Figure 4. Schematic of therapeutic opportunities for targeting astrocytes in AD. As 
outlined within the review various aspects of astrocyte physiology/pathology contribute to 
neurological disorders. Three specific areas are highlighted as indicated above with the 
molecular targets also listed. More detail about the specific transporters can be found in the 
relevant sections of the review. 
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